查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1668178

惡性間皮瘤治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、給藥途徑、最終用戶、地區和競爭細分，2020-2030 年預測

Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球惡性間皮瘤治療市場價值為 2.4565 億美元，預計到 2030 年將達到 3.6011 億美元，預測期內複合年成長率為 6.54%。惡性間皮瘤是一種罕見且侵襲性的癌症，會影響胸部、腹部和心臟的間皮細胞。這種疾病主要與接觸石棉有關，其預後通常不太樂觀。然而，腫瘤學和製藥行業領域的最新進展，促進了惡性間皮瘤治療市場的持續成長。雖然惡性間皮瘤仍然相對罕見，但其發生率在全球範圍內一直在增加。部分原因是診斷延遲和與石棉接觸相關的較長的潛伏期。改進的診斷技術，包括生物標記識別和成像技術，使得更早發現間皮瘤成為可能。早期診斷對於有效治療至關重要。製藥業見證了惡性間皮瘤新療法和治療方法的發展。這些療法包括免疫療法、標靶療法和基因療法，為取得更好的療效帶來了希望。許多國家的政府都推出了法規來限制石棉的使用，這可能會減少未來間皮瘤的病例。此外，醫療改革旨在改善受影響個人獲得治療的機會。在診斷和治療方案進步的推動下，全球惡性間皮瘤治療市場正經歷顯著成長。由於創新療法和日益成長的研究，被診斷出患有這種惡性癌症的患者現在比以往任何時候都擁有更多的希望。儘管挑戰仍然存在，但製藥公司、研究機構和倡導團體的奉獻精神為惡性間皮瘤患者帶來了更光明的未來。

市場概況
預測期 2026-2030
2024 年市場規模 2.4565 億美元
2030 年市場規模 3.6011億美元
2025-2030 年複合年成長率 6.54%
成長最快的領域 培美曲塞
最大的市場 北美洲

主要市場促進因素

惡性間皮瘤發生率不斷上升

主要市場挑戰

認知有限和早期診斷

主要市場趨勢

更加關注免疫療法和標靶療法

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球惡性間皮瘤治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（培美曲塞、順鉑、卡鉑、吉西他濱、長春瑞濱、其他）
    • 依給藥途徑（口服、腸胃外）
    • 按最終用戶（醫院、癌症中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美惡性間皮瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲惡性間皮瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區惡性間皮瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲惡性間皮瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲惡性間皮瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi SA
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 18836

Global Malignant Mesothelioma Therapeutics Market was valued at USD 245.65 Million in 2024 and is expected to reach USD 360.11 Million by 2030 with a CAGR of 6.54% during the forecast period. Malignant mesothelioma is a rare and aggressive form of cancer that affects the mesothelial cells lining the chest, abdomen, and heart. This disease is primarily associated with asbestos exposure, and its prognosis is often bleak. However, recent advancements in the field of oncology and the pharmaceutical industry have given rise to a growing market for malignant mesothelioma therapeutics. While malignant mesothelioma remains relatively rare, its incidence has been increasing globally. This is partly due to delayed diagnoses and the long latency period associated with asbestos exposure. Improved diagnostic techniques, including biomarker identification and imaging technologies, have enabled earlier detection of mesothelioma. Early diagnosis is critical for effective treatment. The pharmaceutical industry has witnessed the development of novel therapies and treatment approaches for malignant mesothelioma. These include immunotherapy, targeted therapy, and gene therapy, which offer hope for better outcomes. Governments in many countries have introduced regulations to restrict asbestos use, which can potentially reduce future cases of mesothelioma. Additionally, healthcare reforms aim to improve access to treatment for affected individuals. The global malignant mesothelioma therapeutics market is witnessing significant growth, driven by advancements in diagnosis and treatment options. Patients diagnosed with this aggressive cancer now have more hope than ever before, thanks to innovative therapies and a growing body of research. While challenges still exist, the dedication of pharmaceutical companies, research institutions, and advocacy groups promises a brighter future for those affected by malignant mesothelioma.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 245.65 Million
Market Size 2030USD 360.11 Million
CAGR 2025-20306.54%
Fastest Growing SegmentPemetrexed
Largest MarketNorth America

Key Market Drivers

Increasing Incidence Rates of Malignant Mesothelioma

Malignant mesothelioma, a rare and aggressive cancer primarily associated with asbestos exposure, has been on the rise globally in recent years. This alarming increase in incidence rates has spurred significant research and development efforts in the field of mesothelioma therapeutics. As more individuals are diagnosed with this devastating disease, the demand for effective treatment options is growing, driving the global malignant mesothelioma therapeutics market forward. According to

Key Market Challenges

Limited Awareness and Early Diagnosis

One of the most significant hurdles in managing malignant mesothelioma is the widespread lack of awareness about the disease, both among the general public and healthcare professionals. Mesothelioma is a rare and aggressive form of cancer, often linked to asbestos exposure, but its symptoms are vague and non-specific, such as chest pain, shortness of breath, and fatigue. These overlapping symptoms are commonly associated with other, more prevalent conditions, which can cause delays in diagnosis. Unfortunately, this leads to diagnoses at later, more advanced stages of the disease, making effective treatment much more difficult. Early detection is key to improving prognosis, but without routine screening methods, identifying mesothelioma at an earlier stage remains a challenge. In addition, because healthcare providers may not regularly suspect mesothelioma in patients with such symptoms, the disease is often misdiagnosed or overlooked until it is too late. Public awareness campaigns, as well as ongoing education for healthcare professionals, are crucial to improving early detection rates and providing patients with better treatment outcomes.

Key Market Trends

Increasing Focus on Immunotherapies and Targeted Therapies

The increasing focus on immunotherapies and targeted therapies is rapidly transforming the Global Malignant Mesothelioma Therapeutics Market. Traditional treatments for mesothelioma, including chemotherapy and radiation, have proven limited in their effectiveness due to the aggressive nature of the disease and its resistance to conventional treatment approaches. In recent years, however, there has been a paradigm shift toward developing more advanced, targeted therapies and immunotherapies that leverage the body's immune system to fight cancer more effectively. In March 2023, Merck, in collaboration with the Canadian Cancer Trials Group (CCTG), has reported that their Phase 2/3 trial, known as CCTG IND.227/KEYNOTE-483, assessing the effectiveness of KEYTRUDA, Merck's anti-PD-1 therapy, combined with chemotherapy, has successfully achieved its primary goal of improving overall survival (OS) in the initial treatment of individuals diagnosed with unresectable advanced or metastatic malignant pleural mesothelioma.

Immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, are showing great promise in mesothelioma treatment. These therapies work by enhancing the body's immune response to tumor cells or by directly targeting the cancerous cells themselves. The success of immunotherapies in other cancers, such as melanoma and non-small cell lung cancer, has sparked increased interest in their application for mesothelioma. Research into the use of immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), in combination with traditional treatments has shown encouraging results, leading to clinical trials and ongoing investigations into their potential.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

Report Scope:

In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malignant Mesothelioma Therapeutics Market, By Drug Type:

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Malignant Mesothelioma Therapeutics Market, By Route of Administration:

  • Oral
  • Parenteral

Malignant Mesothelioma Therapeutics Market, By End User:

  • Hospitals
  • Cancer Centers
  • Others

Malignant Mesothelioma Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Malignant Mesothelioma Therapeutics Market.

Available Customizations:

Global Malignant Mesothelioma Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malignant Mesothelioma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
    • 5.2.2. By Route of Administration (Oral, Parenteral)
    • 5.2.3. By End User (Hospitals, Cancer Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Malignant Mesothelioma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End User

7. Europe Malignant Mesothelioma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End User
    • 7.3.4. France Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End User

8. Asia-Pacific Malignant Mesothelioma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End User
    • 8.3.2. India Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End User

9. South America Malignant Mesothelioma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End User

10. Middle East and Africa Malignant Mesothelioma Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. F. Hoffmann-La Roche Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Merck & Co. Inc.
  • 14.4. Pfizer Inc.
  • 14.5. Eli Lilly and Co.
  • 14.6. Sanofi S.A.
  • 14.7. AstraZeneca Plc
  • 14.8. Bayer AG
  • 14.9. Regeneron Pharmaceuticals Inc.
  • 14.10. GSK Plc

15. Strategic Recommendations

16. About Us & Disclaimer